Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

X
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary) ; Etrumadenant (Primary) ; Hyaluronidase (Primary) ; Motixafortide (Primary) ; Selicrelumab (Primary) ; Simlukafusp alfa (Primary) ; Tiragolumab (Primary) ; Tocilizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Morpheus-Pancreatic Cancer; MORPHEUS-PDAC
  • Sponsors Roche
  • Most Recent Events

    • 08 May 2024 Results published in the Arcus Biosciences Media Release.
    • 08 May 2024 According to an Arcus Biosciences media release, data from this study has been presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2024.
    • 21 Feb 2024 According to Arcus Biosciences media release, data from this study expected to be presented in the first half of 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top